Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Leukemia

  Free Subscription


31.08.2026

2 Am J Hematol
1 Ann Hematol
1 Biochem Biophys Res Commun
6 Blood
1 Bone Marrow Transplant
2 Cancer
1 Eur J Haematol
1 Exp Hematol
1 Genes Chromosomes Cancer
2 J Clin Oncol
1 J Natl Cancer Inst
1 J Pediatr Hematol Oncol
4 Leuk Lymphoma
8 Leukemia
1 Nat Rev Cancer
1 Proc Natl Acad Sci U S A


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. LU P, Yang J, Zhang X, Long J, et al
    Efficacy, Safety, and Kinetics of Naturally Selected Anti-CD7 CAR-T Cell Therapy in T-ALL/LBL With CNS Leukemia.
    Am J Hematol. 2026 Aug 24. doi: 10.1002/ajh.70482.
    PubMed        

  2. WARRAICH M, Kumar S, Fatima M, McCullough K, et al
    Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.
    Am J Hematol. 2026 Aug 23. doi: 10.1002/ajh.70480.
    PubMed         Abstract available


    Ann Hematol

  3. SCHULZ F, Mundt C, Kasprzak A, Jaeger P, et al
    Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.
    Ann Hematol. 2026;105:394.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  4. CHEN S, He Z, Ha Y
    PIP4K2A depletion suppresses AKT signaling and enhances chemotherapy sensitivity in T-cell lymphoblastic lymphoma cells.
    Biochem Biophys Res Commun. 2026;832:154404.
    PubMed         Abstract available


    Blood

  5. CHEN Z, Wu F, Zhang W, Guo W, et al
    Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation.
    Blood. 2026 Aug 25:blood.2026033244. doi: 10.1182/blood.2026033244.
    PubMed         Abstract available

  6. BRAMMER JE, Pflug N, Zambello R, Almeida J, et al
    International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.
    Blood. 2026 Aug 21:blood.2025030252. doi: 10.1182/blood.2025030252.
    PubMed         Abstract available

  7. ABDELBAKY SB, Giacopelli B, Kohlschmidt J, Yamaguchi K, et al
    Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.
    Blood. 2026 Aug 25:blood.2025031899. doi: 10.1182/blood.2025031899.
    PubMed         Abstract available

  8. NOLL JH, Dersh D, Li JY, Hemani H, et al
    T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.
    Blood. 2026 Aug 24:blood.2025032274. doi: 10.1182/blood.2025032274.
    PubMed         Abstract available

  9. RIECKE A, Robrecht S, Yosifov DY, Schneider C, et al
    Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.
    Blood. 2026;148:1108-1114.
    PubMed         Abstract available

  10. CREAMER JP, Ray S, Stewart S, Gulsuner S, et al
    Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.
    Blood. 2026;148:1159-1174.
    PubMed         Abstract available


    Bone Marrow Transplant

  11. WALKER I, Deotare U, Elemary M, Elsawy M, et al
    A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study
    Bone Marrow Transplant. 2026 Aug 21. doi: 10.1038/s41409-026-03024.
    PubMed         Abstract available


    Cancer

  12. ALBLIWI M, Nurse DP, Zabor EC, Hanna J, et al
    Reply to "Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?".
    Cancer. 2026;132:e70593.
    PubMed        

  13. BABU NS, Sangeetha KSS
    Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?
    Cancer. 2026;132:e70592.
    PubMed        


    Eur J Haematol

  14. HOFSTETTER L, Buchrits S, Sherban A, Sternbach N, et al
    Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First-Line Ibrutinib-Venetoclax.
    Eur J Haematol. 2026 Aug 27. doi: 10.1111/ejh.70300.
    PubMed         Abstract available


    Exp Hematol

  15. DUAN J, Zhang H, Chu J, Duan X, et al
    Prognostic model based on calcium-related genes predicts prognosis and reveals the immune landscape of acute myeloid leukemia.
    Exp Hematol. 2026 Aug 25:105870. doi: 10.1016/j.exphem.2026.105870.
    PubMed         Abstract available


    Genes Chromosomes Cancer

  16. NEBRAL K, Konig M, Haslinger S, Inthal A, et al
    Pitfalls and Challenges in the Detection of ZNF384 Rearrangements by Fluorescence in Situ Hybridization.
    Genes Chromosomes Cancer. 2026;65:e70161.
    PubMed         Abstract available


    J Clin Oncol

  17. LACHOWIEZ CA, Zeidner JF, Othman J, Kaempf A, et al
    Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
    J Clin Oncol. 2026;44:2422-2434.
    PubMed         Abstract available

  18. AL-SAWAF O, Zhang C, Esfahani MS, Liu CL, et al
    Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
    J Clin Oncol. 2026 Aug 27:JCO2600161. doi: 10.1200/JCO-26-00161.
    PubMed         Abstract available


    J Natl Cancer Inst


  19. Editor's Note: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1-BCR-ABL-JAK2 Complex.
    J Natl Cancer Inst. 2026 Aug 27:djag260. doi: 10.1093.
    PubMed        


    J Pediatr Hematol Oncol

  20. FARANOUSH M, Qaddoumi I, Mehrvar A, Musakhani H, et al
    Clinical and Epidemiological Characteristics of Infants <6 Months With Leukemia, Neuroblastoma, and Retinoblastoma in a Single Center in Iran.
    J Pediatr Hematol Oncol. 2026 Aug 28. doi: 10.1097/MPH.0000000000003268.
    PubMed         Abstract available


    Leuk Lymphoma

  21. NARKHEDE MS, Blau S, Peevyhouse A, Neuhalfen H, et al
    Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naive CLL/SLL.
    Leuk Lymphoma. 2026;67:2106-2115.
    PubMed         Abstract available

  22. MURPHY DJ, El Hussein S, Applebee A, Thomas A, et al
    Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis.
    Leuk Lymphoma. 2026;67:2057-2063.
    PubMed         Abstract available

  23. XIE Y, Ng I, Liu Y, Wang H, et al
    The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.
    Leuk Lymphoma. 2026 Aug 24:1-11. doi: 10.1080/10428194.2026.2718439.
    PubMed         Abstract available

  24. ACHARYA S, Chauhan R, Dass J, Kv VB, et al
    MLLT10 rearranged acute leukemia-finding order in ambiguity-a case series from a North Indian tertiary care center.
    Leuk Lymphoma. 2026 Aug 26:1-4. doi: 10.1080/10428194.2026.2719275.
    PubMed        


    Leukemia

  25. EICHINGER A, Szmit Z, Kleinschmidt K, Abouqateb M, et al
    Total body irradiation versus chemotherapy before stem cell transplantation in children aged two to four with acute lymphoblastic leukemia-an EBMT pediatric diseases working party study.
    Leukemia. 2026 Aug 21. doi: 10.1038/s41375-026-03114.
    PubMed        

  26. LI Q, Xing P, Xu J, Li J, et al
    Oncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness.
    Leukemia. 2026 Aug 21. doi: 10.1038/s41375-026-03102.
    PubMed         Abstract available

  27. XIA C, Pradhan D, Wang W, Tang Z, et al
    Blastic plasmacytoid dendritic cell neoplasm: ontogeny, immunophenotype, genetics and epigenetics, immune dysregulation, skin tropism and therapeutic implications.
    Leukemia. 2026;40:1868-1878.
    PubMed         Abstract available

  28. BEIRD HC, Kannan S, Liu J, Chen J, et al
    Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
    Leukemia. 2026;40:1951-1960.
    PubMed         Abstract available

  29. BHATIA S, Meng Q, Hageman L, Palmer SB, et al
    Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls.
    Leukemia. 2026 Aug 21. doi: 10.1038/s41375-026-03123.
    PubMed         Abstract available

  30. CAO Z, McCannell KN, Yu S, Budinich KA, et al
    PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.
    Leukemia. 2026 Aug 24. doi: 10.1038/s41375-026-03098.
    PubMed         Abstract available

  31. DANEMAN MR, Meika B, Armendariz L, Tjahjono E, et al
    Cheminformatic identification of small molecules targeting acute myeloid leukemia.
    Leukemia. 2026 Aug 27. doi: 10.1038/s41375-026-03104.
    PubMed         Abstract available

  32. WEI JY, Liu ZW, Lu QS, Qin YJ, et al
    Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.
    Leukemia. 2026;40:1935-1950.
    PubMed         Abstract available


    Nat Rev Cancer

  33. IACOBUCCI I, Mullighan CG
    A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.
    Nat Rev Cancer. 2026;26:689-712.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  34. CABALLERO M, Koren A
    Genetic control of local mutation rates.
    Proc Natl Acad Sci U S A. 2026;123:e2625619123.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum